Editas Medicine, Inc. (EDIT)
Market Cap | 686.94M |
Revenue (ttm) | 25.64M |
Net Income (ttm) | -201.13M |
Shares Out | 68.76M |
EPS (ttm) | -2.94 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 476,768 |
Open | 10.30 |
Previous Close | 9.89 |
Day's Range | 9.78 - 10.30 |
52-Week Range | 7.71 - 21.60 |
Beta | 1.87 |
Analysts | Hold |
Price Target | 15.75 (+57.66%) |
Earnings Date | Feb 23, 2023 |
About EDIT
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pi... [Read more]
Financial Performance
In 2021, EDIT's revenue was $25.54 million, a decrease of -71.85% compared to the previous year's $90.73 million. Losses were -$192.50 million, 66.0% more than in 2020.
Financial StatementsAnalyst Forecast
According to 25 analysts, the average rating for EDIT stock is "Hold." The 12-month stock price forecast is $15.75, which is an increase of 57.66% from the latest price.
News

7 CRISPR Stocks With the Best Long-Term Potential
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease...

Editas Medicine (EDIT) Crossed Above the 50-Day Moving Average: What That Means for Investors
Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?

Editas Medicine (EDIT) Crossed Above the 20-Day Moving Average: What That Means for Investors
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Wall Street Analysts Predict a 72.25% Upside in Editas (EDIT): Here's What You Should Know
The mean of analysts' price targets for Editas (EDIT) points to a 72.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts ...

Editas (EDIT) Moves Ahead With its Portfolio Reprioritization
Editas (EDIT) enters into a deal with Shoreline Biosciences for licensing Editas proprietary gene editing technologies and cell franchise.

Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas' iNK Cell Franchise and Related Gene Editing Technologies
Shoreline to obtain an exclusive license to SLEEK knock-in technology for iPSC-derived NK cells, an exclusive license to SLEEK for iPSC-derived macrophages in oncology and a non-exclusive license for...

3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years
CRISPR could revolutionize the way we treat thousands of diseases. Many of these diseases occur when mutations affect genes, or when people have the wrong amount of genetic material, the Cleveland C...

Editas (EDIT) Dips on Portfolio Reprioritization, To Cut Jobs
Editas (EDIT) enters a restructuring and portfolio reprioritization to focus on hemoglobinopathies and in vivo gene editing. The company is to reduce its workforce by almost 20%.

Editas Medicine tumbles more than 7% after announcing job cuts, restructuring
Editas Medicine Inc. [s: edit] is cutting approximately 20% of its workforce. The company reported 1,800 employees as of May 31, according to its annual report.

Editas Medicine Announces Strategic Updates and Portfolio Reprioritization
Strategic reprioritization of portfolio to focus on hemoglobinopathies and in vivo gene editing

Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the Company's President and CEO Gilmore O'Neill,...

Editas shares jump 9% on positive news from sickle-cell study
Shares of Editas Medicine Inc. EDIT, -4.10% rallied 9.3% in premarket trading on Tuesday after the company said in a news release that it had positive results from the first two patients enrolled in a...

Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease
EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant

Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease
CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a live webinar on, Tuesday, Decembe...

Editas (EDIT) Declines More Than 30% in 3 Months: Here's Why
Editas (EDIT) faces a major setback as it decides to pause enrollment in the phase I/II BRILLIANCE study on EDIT-101, treating Leber congenital amaurosis type 10.

Here's Why Editas (EDIT) Looks Ripe for Bottom Fishing
After losing some value lately, a hammer chart pattern has been formed for Editas (EDIT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revision...

Editas (EDIT) Pauses Eye Disease Study on EDIT-101, Stock Down
Editas (EDIT) pauses enrollment in the phase I/II BRILLIANCE study evaluating EDIT-101 for treating blindness due to Leber congenital amaurosis 10. Stock falls.

Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
EDIT-101 demonstrates a favorable safety profile across all dose cohorts

Editas' (EDIT) Q3 Earnings Beat Estimates, Pipeline in Focus
Editas (EDIT) reports a narrower-than-expected loss for the third quarter of 2022. Focus remains on the lead candidate, EDIT-101, as well as other pipeline candidates.

Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of 6.90% and 99.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Editas Medicine Announces Third Quarter 2022 Results and Business Updates
Dosed second patient with EDIT-301 in the Phase 1/2 RUBY trial for sickle cell disease

Wall Street Analysts Believe Editas (EDIT) Could Rally 139%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 138.9% in Editas (EDIT). While the effectiveness of this highly sought-after metric is questionable, the positi...

Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update
CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that it will host a conference call and webcast on We...

Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting
Studies in non-human primates demonstrated nearly 100% gene editing and knockout of endogenous RHO gene and more than 30% replacement protein levels using a dual vector AAV approach